| CAMX Stock | | | SEK 559.00 4.00 0.71% |
Executive
Mr. Richard Jameson was Chief Commercial Officer at Camurus AB since June 2016. He holds BSC in Applied Biological Sciences from University West of England. He has more than 20 years in the specialty pharmaceutical industry including executive senior positions in sales leadership, marketing, market access and general management for companies which include Serono, Schering Plough, Ferring and Indivior PLC. since 2016.
| Age | 59 |
| Tenure | 8 years |
| Phone | 46 4 62 86 57 30 |
| Web | https://www.camurus.com |
Camurus AB Management Efficiency
The company has return on total asset
(ROA) of
0.0146 % which means that it generated a profit of $0.0146 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0317 %, meaning that it generated $0.0317 on every $100 dollars invested by stockholders. Camurus AB's management efficiency ratios could be used to measure how well Camurus AB manages its routine affairs as well as how well it operates its assets and liabilities.
Camurus AB has accumulated 18.93
M in total debt with debt to equity ratio
(D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Camurus AB has a current ratio of 3.09, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Camurus AB until it has trouble settling it off, either with new capital or with free cash flow. So, Camurus AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Camurus AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Camurus to invest in growth at high rates of return. When we think about Camurus AB's use of debt, we should always consider it together with cash and equity.
Camurus AB , a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 140 people. Camurus AB (CAMX) is traded on Stockholm Exchange in Sweden and employs 170 people.
Management Performance
Camurus AB Leadership Team
Elected by the shareholders, the Camurus AB's board of directors comprises two types of representatives: Camurus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Camurus. The board's role is to monitor Camurus AB's management team and ensure that shareholders' interests are well served. Camurus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Camurus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Never, Independent Director | |
| PerAnders Abrahamsson, Independent Director | |
| Fredrik Tiberg, President, Chief Executive Officer, Director | |
| Fredrik Joabsson, Vice President Business Development and Alliance Management | |
| Kerstin Strinnholm, Independent Director | |
| Annette Mattsson, Vice President - Regulatory Affairs | |
| Rein BSc, VP Relations | |
| Richard Jameson, Chief Commercial Officer | |
| Maria Lundqvist, Global HR | |
| Agneta Svedberg, Vice President, Clinical Development & Pharmacovigilance | |
| Behshad Sheldon, Independent Director | |
| Torsten Malmstrom, Vice President Technical Operations | |
| Peter Hjelmstrom, Chief Officer | |
| Per Wallstrom, Independent Chairman of the Board | |
| Marianne Alexandersson, Independent Director | |
| Eva PinottiLindqvist, Chief Financial Officer | |
| Martin Jonsson, Independent Director | |
| Andrew McLean, VP Counsel | |
| Jon Alonso, Chief Officer | |
| Urban Paulsson, Vice President Corporate Development & General Counsel | |
Camurus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Camurus AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Camurus Stock Analysis
When running Camurus AB's price analysis, check to
measure Camurus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Camurus AB is operating at the current time. Most of Camurus AB's value examination focuses on studying past and present price action to
predict the probability of Camurus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Camurus AB's price. Additionally, you may evaluate how the addition of Camurus AB to your portfolios can decrease your overall portfolio volatility.